EA202091841A1 - Осимертиниб для применения для лечения немелкоклеточного рака легкого - Google Patents
Осимертиниб для применения для лечения немелкоклеточного рака легкогоInfo
- Publication number
- EA202091841A1 EA202091841A1 EA202091841A EA202091841A EA202091841A1 EA 202091841 A1 EA202091841 A1 EA 202091841A1 EA 202091841 A EA202091841 A EA 202091841A EA 202091841 A EA202091841 A EA 202091841A EA 202091841 A1 EA202091841 A1 EA 202091841A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- osimertinib
- lung cancer
- small cell
- cell lung
- cancer treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862629166P | 2018-02-12 | 2018-02-12 | |
| PCT/EP2019/053311 WO2019155059A1 (en) | 2018-02-12 | 2019-02-11 | Osimertinib for use in the treatment of non-small cell lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202091841A1 true EA202091841A1 (ru) | 2020-10-28 |
Family
ID=65443828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202091841A EA202091841A1 (ru) | 2018-02-12 | 2019-02-11 | Осимертиниб для применения для лечения немелкоклеточного рака легкого |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20200368231A1 (https=) |
| EP (2) | EP4431154A3 (https=) |
| JP (2) | JP2021513517A (https=) |
| KR (2) | KR20200119243A (https=) |
| CN (2) | CN116870008A (https=) |
| AU (2) | AU2019219304A1 (https=) |
| BR (1) | BR112020015507A2 (https=) |
| CA (1) | CA3090010A1 (https=) |
| EA (1) | EA202091841A1 (https=) |
| IL (1) | IL276406A (https=) |
| MA (1) | MA51823A (https=) |
| MX (1) | MX2020008395A (https=) |
| SG (1) | SG11202007414XA (https=) |
| TW (2) | TWI868714B (https=) |
| WO (1) | WO2019155059A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3133766A1 (en) | 2019-03-29 | 2020-10-08 | Astrazeneca Ab | Osimertinib for use in the treatment of non-small cell lung cancer |
| CN110433296A (zh) * | 2019-08-16 | 2019-11-12 | 哈尔滨医科大学 | 一种19f-mr/荧光多模式分子成像及载药的诊疗一体化纳米探针及制备方法和应用 |
| WO2021148396A1 (en) * | 2020-01-20 | 2021-07-29 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| WO2022120197A1 (en) * | 2020-12-03 | 2022-06-09 | Emory University | Combinations of epidermal growth factor receptor inhibitors and sterol regulatory element-binding protein inhibitors for uses in cancer therapies |
| WO2022166794A1 (zh) * | 2021-02-02 | 2022-08-11 | 贝达药业股份有限公司 | 埃克替尼在非小细胞肺癌术后辅助治疗中的应用 |
| US20240226101A1 (en) * | 2021-04-30 | 2024-07-11 | Suzhou Puhe BioPharma Co., Ltd. | Pyrimidinylaminobenzenes for lung cancer treatment |
| CN114917231A (zh) * | 2022-05-27 | 2022-08-19 | 杭州师范大学 | β-榄香稀和奥希替尼药物组合在制备抗肺癌药物上的应用 |
| KR102899565B1 (ko) | 2023-02-14 | 2025-12-11 | 박주현 | 좁은 전시공간에서 전시품의 360도 실감 영상투사식 전시장치 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4119551A1 (en) | 2011-07-27 | 2023-01-18 | Astrazeneca AB | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
| GB201400034D0 (en) * | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
| EP3191523B1 (en) * | 2014-09-08 | 2019-08-07 | Yeda Research and Development Co., Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki) |
| WO2016164217A1 (en) * | 2015-04-09 | 2016-10-13 | Clovis Oncology, Inc. | Therapeutic combinations for treating cancer |
| WO2017164887A1 (en) * | 2016-03-25 | 2017-09-28 | OSI Pharmaceuticals, LLC | Pulse dosing regimen and methods for treatment |
| US10813933B2 (en) * | 2016-05-17 | 2020-10-27 | Japanese Foundation For Cancer Research | Therapeutic agent for lung cancer that has acquired EGFR-TKI resistance |
| US20200038398A1 (en) * | 2017-03-10 | 2020-02-06 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
-
2019
- 2019-02-11 JP JP2020541872A patent/JP2021513517A/ja active Pending
- 2019-02-11 TW TW112120315A patent/TWI868714B/zh active
- 2019-02-11 CN CN202310971255.1A patent/CN116870008A/zh active Pending
- 2019-02-11 EP EP24173629.7A patent/EP4431154A3/en active Pending
- 2019-02-11 EA EA202091841A patent/EA202091841A1/ru unknown
- 2019-02-11 SG SG11202007414XA patent/SG11202007414XA/en unknown
- 2019-02-11 KR KR1020207022313A patent/KR20200119243A/ko not_active Ceased
- 2019-02-11 TW TW108104348A patent/TW201941773A/zh unknown
- 2019-02-11 MA MA051823A patent/MA51823A/fr unknown
- 2019-02-11 KR KR1020257043592A patent/KR20260009945A/ko active Pending
- 2019-02-11 MX MX2020008395A patent/MX2020008395A/es unknown
- 2019-02-11 WO PCT/EP2019/053311 patent/WO2019155059A1/en not_active Ceased
- 2019-02-11 US US16/968,912 patent/US20200368231A1/en not_active Abandoned
- 2019-02-11 BR BR112020015507-1A patent/BR112020015507A2/pt unknown
- 2019-02-11 EP EP19705720.1A patent/EP3752153A1/en not_active Withdrawn
- 2019-02-11 CN CN201980012384.XA patent/CN111683663A/zh active Pending
- 2019-02-11 AU AU2019219304A patent/AU2019219304A1/en not_active Abandoned
- 2019-02-11 CA CA3090010A patent/CA3090010A1/en active Pending
-
2020
- 2020-07-30 IL IL276406A patent/IL276406A/en unknown
-
2021
- 2021-10-27 US US17/512,153 patent/US20220184076A1/en not_active Abandoned
-
2022
- 2022-05-05 AU AU2022203007A patent/AU2022203007B2/en active Active
-
2023
- 2023-03-28 US US18/191,219 patent/US20230226059A1/en not_active Abandoned
- 2023-05-26 JP JP2023087054A patent/JP2023116537A/ja active Pending
-
2024
- 2024-01-16 US US18/413,349 patent/US20240156815A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200119243A (ko) | 2020-10-19 |
| JP2023116537A (ja) | 2023-08-22 |
| AU2022203007B2 (en) | 2024-07-04 |
| TW202412804A (zh) | 2024-04-01 |
| US20240156815A1 (en) | 2024-05-16 |
| WO2019155059A1 (en) | 2019-08-15 |
| SG11202007414XA (en) | 2020-09-29 |
| US20230226059A1 (en) | 2023-07-20 |
| AU2022203007A1 (en) | 2022-05-26 |
| CN111683663A (zh) | 2020-09-18 |
| EP3752153A1 (en) | 2020-12-23 |
| MA51823A (fr) | 2021-05-19 |
| KR20260009945A (ko) | 2026-01-20 |
| EP4431154A3 (en) | 2024-12-11 |
| US20220184076A1 (en) | 2022-06-16 |
| CA3090010A1 (en) | 2019-08-15 |
| MX2020008395A (es) | 2020-09-21 |
| BR112020015507A2 (pt) | 2021-01-26 |
| TWI868714B (zh) | 2025-01-01 |
| US20200368231A1 (en) | 2020-11-26 |
| JP2021513517A (ja) | 2021-05-27 |
| IL276406A (en) | 2020-09-30 |
| EP4431154A2 (en) | 2024-09-18 |
| TW201941773A (zh) | 2019-11-01 |
| CN116870008A (zh) | 2023-10-13 |
| AU2019219304A1 (en) | 2020-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202091841A1 (ru) | Осимертиниб для применения для лечения немелкоклеточного рака легкого | |
| EP4706638A3 (en) | Methods of treating heart failure by administering omecamtiv mecarbil | |
| MY199967A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| CL2018001677A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| MY202377A (en) | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin) | |
| MY191040A (en) | Therapy involving antibodies against claudin 18.2 for treatment of cancer | |
| MX2020009773A (es) | Terapia de combinacion. | |
| WO2006014159A3 (en) | Methods of using regenerative cells in the treatment of musculoskeletal disorders | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| MX2021002241A (es) | Uso de linfocitos infiltrantes de tumor para tratar pacientes con carcinoma de pulmón de células no pequeñas (nsclc) refractario al anticuerpo anti muerte programada 1 (pd-1). | |
| EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| WO2019157056A8 (en) | Treatment of patients with classic fabry disease | |
| EA201691385A1 (ru) | Комбинированная терапия рака | |
| WO2006022612A3 (en) | Methods of using regenerative cells in the treatment of stroke and related diseases and disorders | |
| WO2020243273A3 (en) | Methods of treating cholangiocarcinoma | |
| MX2020010121A (es) | Compuestos con actividad antitumoral contra celulas de cancer que portan las mutaciones del exon 19 del receptor 2 del factor de crecimiento epidermico humano. | |
| MX2025002967A (es) | Composicion farmaceutica y uso de la misma | |
| PH12022550721A1 (en) | Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma | |
| EA202092043A1 (ru) | Композиции и способы для лечения рака легкого на поздней стадии | |
| RU2024101250A (ru) | Фармацевтические комбинации, содержащие ингибитор kras g12c, и варианты их применения для лечения видов рака | |
| MX2025014596A (es) | Metodos para tratar la dermatomiositis con brepocitinib | |
| IL314600A (en) | Combination therapy for use in treatment of non-small cell lung cancer | |
| UA129745U (uk) | Спосіб лікування хворих на бронхіальну астму з ішемічною хворобою серця | |
| UA131699U (uk) | Спосіб лікування хронічного обструктивного захворювання легень у хворих на герпетичну інфекцію | |
| UA116484U (uk) | Cпосіб лікування артеріальної гіпертензії з метаболічним синдромом |